United States · FDA National Drug Code directory
VYVGART Hytrulo
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 73475-3102_a2607d4b-76e8-4004-94c2-190fdc8593fb
- Product NDC
- 73475-3102
- Form
- INJECTION, SOLUTION
- Composition / generic term
- efgartigimod alfa and hyaluronidase (human recombinant)
- Labeler
- argenx US
- Marketing category
- BLA
- Marketing start / end (source format)
- 20230620
- Source listing expiry
- 20271231
Source-listed ingredients
- EFGARTIGIMOD ALFA — 180 mg/mL
- HYALURONIDASE (HUMAN RECOMBINANT) — 2000 U/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-DOSE in 1 CARTON (73475-3102-3) / 5.6 mL in 1 VIAL, SINGLE-DOSE · 73475-3102-3
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →